istock-544671212_stockstudiox
stockstudiox / iStockphoto.com
27 March 2020Big PharmaRory O'Neill

Canada authorises compulsory licences for COVID-19 shortfalls

Canada is the latest country to adopt  emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2020   Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Big Pharma
21 April 2022   Nova Chemicals has asked Canada’s top court to revisit a historic patent damages award of CAD$645 million won by Dow Chemical at the country’s federal court of appeal.

More on this story

Big Pharma
21 April 2022   Nova Chemicals has asked Canada’s top court to revisit a historic patent damages award of CAD$645 million won by Dow Chemical at the country’s federal court of appeal.
Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Americas
30 April 2020   Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.

More on this story

Big Pharma
21 April 2022   Nova Chemicals has asked Canada’s top court to revisit a historic patent damages award of CAD$645 million won by Dow Chemical at the country’s federal court of appeal.
Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Americas
30 April 2020   Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.